Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience
| العنوان: | Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience |
|---|---|
| المؤلفون: | Huiying Qiu, Chongmei Huang, Xiaoqian Xu, Jianmin Yang, Xiong Ni, Shuqing Lü, Xiao-Xia Hu, Jianmin Wang |
| المصدر: | International Journal of Hematology. 89:34-38 |
| بيانات النشر: | Springer Science and Business Media LLC, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Neutropenia, Gastroenterology, Dexamethasone, Bortezomib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Epirubicin, business.industry, Remission Induction, Hematology, Middle Aged, medicine.disease, Boronic Acids, Survival Analysis, Hematopoietic Stem Cell Mobilization, Thalidomide, Surgery, Regimen, Treatment Outcome, Pyrazines, Blood Component Removal, Female, Liver function, Multiple Myeloma, business, medicine.drug |
| الوصف: | The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM). The BADT regimen consisted of a maximum of eight 4-week cycles of: intravenous bortezomib (1.0 mg/m(2)) and intravenous epirubicin (12 mg/m(2)) on days 1, 4, 8, and 11; dexamethasone (20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12; and oral thalidomide (100 mg/m(2)) on days 1-28. Twelve patients with MM were included in the study, of whom four had not been previously treated and eight had been previously treated with at least one cycle of a systemic combined regimen. All the patients completed at least two cycles of treatment, with an average of five cycles; the complete response (CR) rate was 83.3% (10/12) and stabilization of disease was 16.7% (2/12). The average number of cycles required to achieve CR was 1.9 (range 1-6). In three patients, mobilization of peripheral blood stem cells allowed a sufficient quantity of CD34+ cells to be harvested for future autotransplantation. The main adverse reactions included peripheral neuropathy (4/12), thrombocytopenia (3/12), electrocardiographic abnormalities (4/12), neutropenia (5/12), and liver function impairment (4/12), primarily grade I-II. Infection occurred in four patients with neutropenia, including one patient who developed sepsis. The estimated 1-year overall survival rate was 91.7 +/- 8.0%, and the estimated 1-year disease-free survival was 75.0 +/- 12.5%. BADT is a highly effective combined regimen, with acceptable toxicity, for the treatment of multiple myeloma. |
| تدمد: | 1865-3774 0925-5710 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5e32fe3e43833bf167e0fb2bfd8566Test https://doi.org/10.1007/s12185-008-0218-9Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....ff5e32fe3e43833bf167e0fb2bfd8566 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18653774 09255710 |
|---|